We are live on
!
Find out more
Balyasny Asset Management Portfolio holdings
AUM
$77.1B
1-Year Est. Return
42.89%
This Fund
S&P 500
This Quarter
Est. Return
+7.96%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+1,026.86%
AUM
$78.8B
AUM Growth
-$135M
(-0.17%)
Cap. Flow
-$4.13B
Cap. Flow
% of AUM
-5.25%
Top 10 Holdings %
Top 10 Hldgs %
14.64%
Holding
3,669
New
809
Increased
1,002
Reduced
1,102
Closed
643
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$807M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$497M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$390M |
| 4 |
Kenvue
KVUE
|
+$379M |
| 5 |
Broadcom
AVGO
|
+$324M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$409M |
| 2 |
Visa
V
|
+$354M |
| 3 |
Advanced Micro Devices
AMD
|
+$328M |
| 4 |
Meta Platforms (Facebook)
META
|
+$317M |
| 5 |
Lockheed Martin
LMT
|
+$316M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.61% |
| 2 | Consumer Discretionary | 9.64% |
| 3 | Healthcare | 8.17% |
| 4 | Industrials | 8.1% |
| 5 | Financials | 8.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2876
RXO
RXO
$3.75B
| $136K | ﹤0.01% |
+10,763
| New | +$159K |
|
2877
DiaMedica Therapeutics
DMAC
$370M
| $136K | ﹤0.01% |
+17,086
| New | +$128K |
|
2878
SmartRent
SMRT
$282M
| $133K | ﹤0.01% |
+65,862
| New | +$108K |
|
2879
Fractyl Health
GUTS
$111M
| $132K | ﹤0.01% |
+60,219
| New | +$96.9K |
|
|
FBRT
2880
Franklin BSP Realty Trust
FBRT
$675M
| $131K | ﹤0.01% |
13,093
-113,809
| -90% | -$1.19M |
|
2881
Westrock Coffee
WEST
$816M
| $127K | ﹤0.01% |
+31,181
| New | +$137K |
|
2882
Designer Brands
DBI
$315M
| $127K | ﹤0.01% |
+17,078
| New | +$82.1K |
|
2883
Kelly Services Class A
KELYA
$530M
| $125K | ﹤0.01% |
+14,250
| New | +$145K |
|
|
CTLP
2884
CALL
DELISTED
Cantaloupe
CTLP
| $120K | ﹤0.01% |
11,300
| – | – |
|
2885
AtaiBeckley Inc
ATAI
$2.68B
| $118K | ﹤0.01% |
28,957
-89,917
| -76% | -$424K |
|
2886
Alto Ingredients
ALTO
$320M
| $117K | ﹤0.01% |
+40,605
| New | +$76.6K |
|
2887
Rayonier Advanced Materials
RYAM
$578M
| $117K | ﹤0.01% |
+19,786
| New | +$129K |
|
|
RWT
2888
Redwood Trust
RWT
$592M
| $116K | ﹤0.01% |
20,974
-38,711
| -65% | -$213K |
|
2889
Cabaletta Bio
CABA
$455M
| $113K | ﹤0.01% |
+51,552
| New | +$128K |
|
2890
Fossil Group
FOSL
$312M
| $113K | ﹤0.01% |
+30,014
| New | +$84.7K |
|
|
AWF
2891
AllianceBernstein Global High Income Fund
AWF
$877M
| $111K | ﹤0.01% |
10,363
-18,343
| -64% | -$199K |
|
2892
Pitney Bowes
PBI
$2.26B
| $110K | ﹤0.01% |
10,365
-6,812
| -40% | -$70.6K |
|
2893
Agilon Health
AGL
$1.49B
| $107K | ﹤0.01% |
6,231
-5,507
| -47% | -$107K |
|
2894
Critical Metals Corp
CRML
$980M
| $107K | ﹤0.01% |
15,402
-15,782
| -51% | -$172K |
|
2895
IHS Holding
IHS
$2.81B
| $107K | ﹤0.01% |
14,303
-206
| -1% | -$1.42K |
|
2896
Capitol Federal Financial
CFFN
$1.1B
| $106K | ﹤0.01% |
15,638
-1,999
| -11% | -$13K |
|
2897
ImmunityBio
IBRX
$8.13B
| $102K | ﹤0.01% |
51,640
+33,914
| +191% | +$76.8K |
|
2898
loanDepot
LDI
$286M
| $102K | ﹤0.01% |
49,381
+34,305
| +228% | +$95.3K |
|
2899
Holley
HLLY
$381M
| $102K | ﹤0.01% |
+24,650
| New | +$88.8K |
|
2900
Payoneer
PAYO
$2.4B
| $102K | ﹤0.01% |
18,064
-913,729
| -98% | -$5.28M |
|
Similar funds
CBU
BC
Balyasny Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Balyasny Asset Management held 3,669 positions worth $78.8B, down 0.17% from $78.9B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Balyasny Asset Management withdrew a net $4.13B in Q4 2025, closing 643 positions and reducing 1,102 holdings. Its most notable exit was Mr. Cooper, an estimated $277M position sold in full.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 12% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Balyasny Asset Management opened a new position in Avidity Biosciences worth $436M.
- Balyasny Asset Management's largest Q4 2025 buy was Avidity Biosciences: 6,040,590 shares worth $436M.
- Balyasny Asset Management added most to Amazon in Q4 2025, an estimated $807M increase.
- Balyasny Asset Management's biggest Q4 2025 reduction was Apple, cutting an estimated $409M.
- Balyasny Asset Management fully exited Mr. Cooper in Q4 2025, selling an estimated $277M.
- Balyasny Asset Management's ten largest holdings make up 15% of its $78.8B portfolio in Q4 2025.
- Balyasny Asset Management opened 809 new positions and closed 643 in Q4 2025.
- Balyasny Asset Management's portfolio value fell 0.17% quarter-over-quarter to $78.8B.
Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.